← Back to Clinical Trials
Recruiting NCT06034834

Near-Infrared Imaging for Perfusion Assessment of Traumatic Soft Tissue and Skeletal Injuries

Trial Parameters

Condition Perfusion
Sponsor Leiden University Medical Center
Study Type INTERVENTIONAL
Phase N/A
Enrollment 120
Sex ALL
Min Age 18 Years
Max Age N/A
Start Date 2023-11-13
Completion 2025-09-10
Interventions
Near-infrared fluorescence imaging of perfusion

Brief Summary

To date, intraoperative assessment of tissue and bone viability is predominantly subjective, depending on the clinical view of the surgeon, resulting in a variation in the thoroughness of debridement. Inadequate initial resection leads to multiple debridement interventions, leading to prolonged hospitalization or readmission with consequently high direct medical costs. Near-Infrared Fluorescence (NIRF) imaging with Indocyanine Green (ICG) could potentially be a relevant contribution to adequately treating soft tissue and skeletal injuries by creating an improved distinction between viable and non-viable tissue, based on perfusion indices. This study evaluates whether intraoperative perfusion assessment with ICG fluorescence imaging is a feasible and quantifiable technique for treating traumatic injuries.

Eligibility Criteria

Inclusion Criteria: In order to be eligible to participate in this study, a subject must meet all the following criteria: * Age ≥ 18 years * Diagnosed with one or more of the following injuries: * Crush injury * Open deglovement * Open fracture(s) (Gustilo 3, -A, -B \& -C) * Non-union tibia/clavicula/ulna/humerus/rib * Fracture related infection * Indication for surgical intervention Exclusion Criteria: A potential subject who meets any of the following criteria will be excluded from participation in this study: * Hemodynamically unstable due to severe blood loss * Allergic or hypersensitive to iodine/crustaceans/shellfish * Diagnosed with endocrine thyroid disorders (hyperthyroidism) * Pregnancy * Diagnosed with impaired renal function eGFR \<30 L/min/1.73m2 * Diagnosed with severely disturbed hepatic enzymes/liver failure

Related Trials